Who is the parent company behind Wegovy?

Novo Nordisk's role: more than just a name on the box

Novo Nordisk has spent over a century focused on metabolic disease, which is why semaglutide (the active molecule in Wegovy) has one of the most thoroughly documented clinical histories of any weight-management medicine. The company ran the STEP trial programme to build the evidence base for Wegovy's weight-management licence; STEP 1, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose.

Beyond injections, Novo Nordisk continued developing semaglutide in tablet form. The MHRA approved Wegovy tablets on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine specifically for weight management. That approval came from OASIS 4 trial data showing roughly 13.6% average weight loss over 64 weeks, or around 17% among participants who remained fully adherent throughout the trial period.

Knowing the manufacturer matters in one practical way: supply. If you want to understand the Wegovy company behind every pen and tablet sold in the UK, Novo Nordisk controls manufacturing capacity for all of it. Shortages in 2023 and 2024 were a direct result of demand outpacing Novo Nordisk's production ramp. If you want a quick sense of current availability, checking whether Novo Nordisk's UK site acknowledges any supply situation takes under a minute and is worth doing before you commit to a provider.

Novo Nordisk versus Eli Lilly: two companies, two different medicines

It is easy to conflate the two biggest names in weight-loss medicine, but they are separate companies making distinct products. If you have been researching the Wegovy drug company, Novo Nordisk is the one making semaglutide (Wegovy), while Eli Lilly makes tirzepatide (Mounjaro). The difference is not merely branding: semaglutide activates GLP-1 receptors only, while tirzepatide targets both GLP-1 and GIP receptors, making it the only dual-agonist weight-loss medicine currently licensed in the UK.

You can read more about semaglutide as the active ingredient or explore the full Wegovy overview to see how the injection and tablet compare on the same page. If you are weighing Wegovy against Mounjaro, the treatment options page sets out the key differences across both.

NICE has issued separate technology appraisals for each: TA875 for semaglutide and TA1026 for tirzepatide. The eligibility thresholds, NHS availability timelines, and clinical criteria differ between them. A prescriber considers which medicine fits your health picture; manufacturer prestige is not part of that calculation.

Does Novo Nordisk's ownership affect the price you pay?

Yes, in a direct sense. People often ask what company makes Wegovy, and the answer, Novo Nordisk, matters here because it sets the UK list price from which private pharmacies build their own pricing. Eli Lilly made a significant list-price adjustment to Mounjaro from September 2025; Novo Nordisk's own pricing decisions similarly shape what you see quoted across providers. For context on what Wegovy typically costs in the UK private market, the Wegovy price page covers the current range without the surprises that come from providers who advertise a headline figure and add fees later.

The manufacturer relationship also shapes whether your medicine arrives through a legitimate supply chain. Wegovy dispensed by a GPhC-registered pharmacy comes via Novo Nordisk's authorised UK distribution network. Counterfeit weight-loss pens (which the MHRA has repeatedly warned about, most notably in its Yellow Card reporting system) do not. A quick check of any online pharmacy on the GPhC register before you order is the most straightforward way to confirm you are getting the genuine article.

How this shapes your decision about where to get treatment

The parent company question is really a supply-chain and legitimacy question in disguise. Novo Nordisk authorises UK distributors; GPhC-registered pharmacies buy from those distributors; prescribers assess your suitability; you receive genuine medicine. Every step in that chain has a regulator behind it.

At nume, Wegovy is sourced through the licensed UK supply chain and dispensed from our GPhC-registered pharmacy. Consultations are read by a named GPhC-registered Independent Prescriber, not processed automatically. If you are ready to find out whether Wegovy is clinically appropriate for you, a free consultation is the right starting point — the prescriber reviews your answers the same day. Check your eligibility and start your free consultation when you are ready.